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Polyphenols have recently become an important focus of study in obesity research. Oligonol is an oligomerized polyphenol,
typically comprised of catechin-type polyphenols from a variety of fruits, which has been found to exhibit better bioavailability and
bioreactivity than natural polyphenol compounds.Here, we demonstrated thatOligonol inhibits 3T3-L1 adipocyte differentiation by
reducing adipogenic gene expression. During adipogenesis, Oligonol downregulated the mRNA levels of peroxisome proliferator-
activated receptor 𝛾 (PPAR𝛾), CCAAT/enhancer binding proteins 𝛼 (C/EBP𝛼), and 𝛿 (C/EBP𝛿) in a dose-dependent manner and
the expression of genes involved in lipid biosynthesis. The antiadipogenic effect of Oligonol appears to originate from its ability to
inhibit the Akt and mammalian target of rapamycin (mTOR) signaling pathway by diminishing the phosphorylation of ribosomal
protein S6 kinase (p70S6K), a downstream target ofmTOR and forkhead box proteinO1 (Foxo1).These results suggest that Oligonol
may be a potent regulator of obesity by repressing major adipogenic genes through inhibition of the Akt signaling pathway, which
induces the inhibition of lipid accumulation, ultimately inhibiting adipogenesis.
1. Introduction
Obesity is rapidly becoming a global health problem and
is a leading cause of metabolic syndrome, cardiovascular
diseases, and type II diabetes. Obesity may be attributed
to a number of factors, including changes in genetic pre-
dispositions, eating habits, and lack of exercise. One of the
mechanisms proposed to explain the cause of obesity is
an increase in adipose tissue resulting from an increase in
the number of fat cells (adipocytes) through adipogenesis,
leading to a subsequent increase in lipid accumulation in
adipose tissue. Therefore, finding an effective strategy to
suppress adipogenesis is of significant interest in the field of
antiobesity research.
Adipogenesis involves the development of fat cells when
undifferentiated preadipocytes are converted to fully differ-
entiated, mature adipocytes. The mechanism of adipogenesis
is tightly regulated by several key transcription factors.
However, it is difficult to dissect the phases of adipogenesis
in vivo due to heterogenic differentiation of adipose tissue,
which occurs throughout the lifetime of an organism. The
establishment of the 3T3-L1 cell line has provided us with
an opportunity to study adipocyte differentiation. Although
its morphology is indistinguishable from that of fibroblasts,
this cell line is committed to the adipocyte lineage. Treatment
with a mixture of insulin, dexamethasone, and 3-isobutyl-1-
methylxanthine induces the adipogenic differentiation pro-
cess in 3T3-L1 cells [1].
Peroxisome proliferator-activated receptor 𝛾 (PPAR𝛾)
and CCAAT/enhancer binding proteins (C/EBP𝛼, C/EBP𝛽,
and C/EBP𝛿) are key transcription factors in adipogenesis.
C/EBP𝛽 and C/EBP𝛿 are induced during the early phases of
adipogenesis. Activation of these transcriptional components
is then followed by activation of PPAR𝛾 and C/EBP𝛼,
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the central transcriptional regulators in adipogenesis.
Once PPAR𝛾 and C/EBP𝛼 are activated, they cooperatively
enhance each other, which then induces further expression
of adipogenic genes required for maintaining adipocyte
characteristics and terminal differentiation [1, 2]. In
particular, PPAR𝛾 is a central regulator of adipogenesis and
represents a good target for antiobesity therapy.
Flavonoids and polyphenols are natural chemical com-
pounds derived from fruits and vegetables and are known to
function as anti-inflammatory and chemopreventive agents
on various human diseases. Both in vivo and in vitro
studies have demonstrated that flavonoids and polyphenols
can be used to treat neurological, metabolic, cardiovascular,
and psychiatric diseases [3]. However, due to their high
molecular weights, polyphenol polymers exhibit inefficient
bioreactivity and poor bioabsorption. In order to overcome
these limitations, a novel technology was used to optimize
the oligomerization of polyphenol polymers. Oligonol is an
oligomerized polyphenol, typically comprised of catechin-
type polyphenols from a variety of fruits (e.g., grapes, apples,
and persimmons). A typical polyphenol contains less than
10% oligomers, whereas Oligonol consists of more than 50%
oligomers (i.e., monomers to pentamers) [3]. It is interesting
to note that synthetic Oligonol has thus far exhibited better
bioavailability than natural polyphenol compounds [4] and
appears to be safe for human use at doses lower than
200mg/day [5].
Several studies have reported the antiobesity effects of
Oligonol. Oral administration of Oligonol decreases white
adipose tissue mass and attenuates dysregulated expression
of adipokines in adipose tissues of mice consuming high fat
diets [6].The same research group also reported thatOligonol
enhances lypolysis in primary adipocytes through activation
of the extracellular signaling-regulated kinases 1/2 (ERK1/2)
pathway accompanied by downregulation of perilipin [7].
However, the potential antiobesity effects of Oligonol on
adipogenesis are not known; therefore, the aim of this
present study was to investigate whether Oligonol inhibits
the adipogenic process using 3T3-L1 cells, a well-established
model system, to elucidate the underlying molecular mecha-
nisms of Oligonol-inducedmodification of in vitro adipocyte
differentiation.
2. Materials and Methods
2.1. Materials. The 3T3-L1 cells were graciously provided by
Dr. Jae-Woo Kim (Yonsei University, College of medicine).
Oligonol was supplied by KCF Korea Co. (Seoul, Korea). The
triglyceride quantification kit was purchased from BioVision
(Mountain View, CA, USA). Antibodies for experiments
are the following: CEBP𝛼, pACC(Ser79), ACC, FAS, pAKT
(Ser473), AKT, pFOXO1(Thr24), FOXO, pAMPK(Thr172),
AMPK, pmTOR(Ser2448), mTOR, pS6K(Thr389), S6K, pS6
(Cell Signaling, Danvers, MA, USA), PPAR𝛾, GLUT4,
Adiponectin (Santa Cruz Biotechnology, Santa Cruz, CA,
USA), aP2 (Cayman, Ann Arbor, MI, USA), and 𝛽-actin
(Sigma-Aldrich, Oakville, Canada).
2.2. Cell Culture. 3T3-L1 preadipocytes were maintained in
Dulbecco’s modified eagle medium (DMEM) containing 10%
calf serum at 37∘C and 5% CO
2
. After reaching confluence,
differentiation to adipocytes was induced by treatment with
insulin, dexamethasone (DEX), and isobutylmethylxanthine
(IBMX) in DMEM containing 10% FBS for 2 days (DM1).
The medium was replaced with DMEM containing insulin
for additional 2 days (DM2) and then replaced with fresh
DMEM containing 10% FBS every other day. Oligonol was
dissolved in ethanol, directly diluted in DMEM, and treated
during the course of differentiation. The final concentration
of the ethanol did not exceed 0.1% for either the control or the
treated cells for all experiments.
2.3. MTT Assay. For initial screening of cytotoxicity, 3T3-
L1 preadipocytes were grown in a 96-well plate with various
concentrations of Oligonol for 24 hrs. After determination of
cytotoxic dose of Oligonol, cells were treated with 10, 25, or
50 𝜇g/mL of Oligonol for 4 days after induction of differenti-
ation (from day 4 to day 8), or for 8 days during entire experi-
ments. Cell viability was determined colorimetrically using 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT). Insoluble formazan crystals were dissolved in iso-
propanol, and absorbance was measured at 490 nm using a
microplate reader (Molecular Devices, Mountain View, CA,
USA).
2.4. Oil Red O Staining and Quantification. Fully differ-
entiated 3T3-L1 cells were washed twice with PBS and
fixed in 4% paraformaldehyde for 1 h. Cells were stained
with 3 g/L of Oil Red O (Sigma Chemical, St. Louis, MO)
in 60% isopropanol at room temperature for 10min and
washed extensively with distilled water. Pictures were taken
using a microscope (Axiovert 40CFL; Olympus, Germany).
In addition, stained Oil Red O dye was extracted with
isopropanol and collected, and the absorbance (O.D. 500 nm)
was measured by microplate reader (Versamax; Molecular
Devices Corporation, CA, USA).
2.5. Quantitative Real-Time PCR. Total RNA from 3T3-L1
cells was isolated using an RNeasy mini kit (Qiagen, Hilden,
Germany). Aliquots of 2 𝜇g of total RNA were used to
synthesize cDNAusing theQuantiTechReverse transcription
kit (Qiagen, Hilden, Germany) according to the manufac-
turer’s instructions. After reverse transcription, samples were
analyzed by SYBR premix Ex Taq using Takara Thermal
Cycler dice real-time system (Otsu, Shiga, Japan).
Each cDNA was amplified (95∘C for 5 s, 58–64∘C for
10 s, and 72∘C for 20 s for 40 cycles) using specific primers
designed from sequences derived from the NCBI nucleotide
sequence database (Table 1). All reactions were performed in
triplicate, and the data were normalized to GAPDH as an
internal control.
2.6.Western Blot Analysis. Cells were extracted in the extrac-
tion buffer (50mM Tris HCl, pH 8.0, 5mM EDTA, 150mM
NaCl, 0.5% sodium deoxycholate, 1% Nonidet P-40, 0.1%
SDS, 1mM PMSF, 1mM NaF, 1mM NaVO
4
, and protease
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Table 1: Sequence of primers used for RT-PCR.
Genes Forward primer Reveres primer Tm (∘C)
PPAR𝛾 CTTGTGAAGGATGCAAGGGT ATACAAATGCTTTGCCAGGG 62
C/EBP𝛼 TTGAAGCACAATCGATCCATCC GCACACTGCCATTGCACAAG 64
C/EBP𝛽 ACCGGGTTTCGGGACTTGA CCCGCAGGAACATCTTTAAGTGA 58
C/EBP𝛿 TGATCTGCACGGCCTGTTGTA GCACTTTGGGCAGGGATTTG 60
aP2 TGGGAACCTGGAAGCTTGTCTC GAATTCCACGCCCAGTTTGA 60
GLUT4 GCTTTGTGGCCTTCTTTGAG CAGGAGGACGGCAAATAGAA 60
Adiponectin GAAGATGACGTTACTACAAC TCAGTTGGTATCATGGAAGA 58
ACC GAAGTCAGAGCCACGGCACA GGCAATCTCAGTTCAAGCCAGTC 62
FAS AGCACTGCCTTCGGTTCAGTC AAGAGCTGTGGAGGCCACTTG 62
SCD TCTTGTCCCTATAGCCCAATCCAG AGCTCAGAGCGCGTGTTCAA 62
FDPS ACACGCCAATGCCCTGAAG AGCCAGCTGCATTTGTTGTCC 62
GAPDH TGAACGGGAAGCTCACTGG TCCACCACCCTGTTGCTGTA 58–64
inhibitor cocktails (Roche, Germany)). Equal amounts of
protein extracts were separated on 10% polyacrylamide
gels and electrophoretically transferred onto polyvinylidene
fluoride membrane (Gelman Laboratory, MI, USA). After
blocking, the membranes were incubated with each primary
antibody and then with HRP-conjugated IgG (Santa Cruz
Biotechnology, Santa Cruz, CA, USA). The blots were devel-
oped using an ECL detection kit.
2.7. Triglyceride Assay. Triglyceride content was determined
using an EnzyChrom Triglyceride Assay kit (BioAssays, Hay-
ward,CA,USA) according to themanufacturer’s instructions.
Briefly, Oligonol was used to treat 3T3-L1 adipocytes 8 days
after their differentiation. For cellular triglyceride analysis,
cells were washed with PBS and solubilized in 5% Triton X-
100. Colorimetric intensity was determined at 570 nm, and
quantification was performed using a 96-well plate reader
(Molecular Devices, Mountain View, USA).
2.8. Glycerol Assay. 3T3-L1 adipocytes were fully differenti-
ated for 8 days and then treated with different concentration
ofOligonol for 24 and 48 hrs. After treatment of differentiated
3T3-L1 cells with Oligonol, free glycerol contents in the cell
supernatants were quantified using a glycerol quantification
kit according to the manufacturer’s instructions (Biovision
Inc., Milpitas, USA). Glycerol was quantified at 570 nm on
a 96-well plate reader (Molecular devices, Mountain View,
USA).
2.9. Statistics. The data are shown as mean ± SEM. Differ-
ences between means of each group were analyzed using
Student’s 𝑡-test or one-way ANOVA test with Dunnett’s
multiple comparison test. 𝑃 values of <0.05 were considered
significant.The statistical software package Prism 5.0 (Graph-
Pad Software, La Jolla, CA, USA) was used for the analysis.
3. Results
3.1. Effect of Oligonol on 3T3-L1 Differentiation. To test any
possible toxic effects ofOligonol on 3T3-L1 cells, we evaluated
cell viability and cytotoxicity using the MTT assay. 3T3-L1
cells were incubated with various concentrations of Oligonol
for 24 hrs, and the percentage of cell viability was determined
compared to control cells (set as 100%). We observed 90% or
higher cell viability when 3T3-L1 cells were treated with up to
250 𝜇g/mL of Oligonol for 24 hrs. Since mild toxicity during
adipocyte differentiation was observed with Oligonol con-
centrations exceeding 250 𝜇g/mL, subsequent experiments
were conducted using Oligonol at concentrations less than
or equal to 50 𝜇g/mL. When 3T3-L1 cells were treated
with Oligonol for 8 days during adipocyte differentiation,
50 𝜇g/mL of Oligonol showed mild inhibitory effect on cell
viability on day 8 by MTT assay; however, there was no sign
of cytotoxicity or cell death, and cells were morphologically
similar to preadipocytes. When cells were treated with the
same doses of Oligonol from day 4 to day 8 after induction
of differentiation with differentiation cocktail (insulin, DEX,
and IBMX) treatment with Oligonol did not show any
significant inhibitory effect on cell viability in adipocytes
(Figure 1(a)).
Based on previous reports indicating the beneficial effects
of polyphenol compounds for treating obesity, we investi-
gated whether Oligonol inhibits adipocyte differentiation.
3T3-L1 preadipocytes were maintained in a differentiated
medium for 8 days in the absence or presence of 10, 25, or
50 𝜇g/mL of Oligonol. Fully differentiated 3T3-L1 adipocytes
were stained, and total lipid accumulation was quantified
by Oil Red O. Fully differentiated adipocytes are charac-
terized by lipid droplets filling the cytoplasmic space of
the cells. In contrast to the control cells, cells incubated
with Oligonol showed reduced numbers of lipid droplet—
containing cells in a dose—dependent manner, and the
few vesicles detected under a microscope were smaller in
size (Figure 1(b)). Oligonol also significantly reduced total
cytosolic lipid content compared to control cells (Figure 1(c)),
which was in agreement with observations from phase con-
trast microscopy (Figure 1(b)). It was notable that substantial
decrease of lipid accumulation was not due to cytotoxic
effect, because both control cells and drug-treated cells were
grown in comparable cell densities. Oligonol treated cells
maintained fibroblast-like preadipocyte appearance without
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Figure 1: Effect of Oligonol on 3T3-L1 adipocytes. (a) Cell viability of 3T3-L1 preadipocytes and differentiated adipocytes treated with
Oligonol (OLG). 3T3-L1 preadipocytes were incubated with various concentrations of Oligonol (0–500𝜇g/mL) for 24 hrs and cell viability
was measured byMTT assay. 3T3-L1 preadipocytes were differentiated into adipocytes with theMDI (mixture of IBMX, dexamethasone, and
insulin)—containingmedia for 8 days. Cells were treated with 10, 25, or 50𝜇g/mL of Oligonol during entire differentiation period (from day 0
to day 8) or after induction of differentiation (from day 4 to day 8). (b) Lipid accumulation was determined by Oil Red O staining. (c) Cellular
lipid accumulation was quantified bymeasuring the absorbance at 500 nm. Values are mean ± SEM of three independent experiments carried
out in triplicates. ∗𝑃 < 0.05, ∗∗𝑃 < 0.01 compared with untreated control.
disrupting the integrity of a cell monolayer as monitored
under microscope during adipocyte differentiation. These
results demonstrated that Oligonol prevented adipocyte
differentiation in 3T3-L1 without affecting cell growth or
viability.
3.2. Effect of Oligonol on the Expression of Adipocyte-
Specific Transcription Factors during 3T3-L1 Differentiation.
Adipocyte differentiation is accompanied by the increased
expression of various adipocyte-associated transcription fac-
tors. To investigate the mechanisms underlying Oligonol-
induced inhibition of 3T3-L1 differentiation in detail, we first
examined which transcription factors could be affected by
Oligonol. Transcription factors, such as C/EBP𝛼, C/EBP𝛽,
C/EBP𝛿, and PPAR𝛾, are known to be key markers in the
adipogenic process, especially during the early and middle
stages of adipogenesis [8]. These transcription factors are
highly induced during adipogenesis; therefore, we treated
3T3-L1 cells in the process of differentiationwith various con-
centrations of Oligonol, and determined the gene expression
of each transcription factor by quantitative RT-PCR.
mRNA levels of the transcription factors PPAR𝛾, C/EBPs
were significantly increased at day 2, and gradually declined
at days 4 and 8 during adipocyte differentiation. Treatment
of Oligonol reduced mRNA levels of PPAR𝛾, C/EBP𝛼,
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Figure 2: Effect of Oligonol on the expression of adipocyte-specific transcription factors during 3T3-L1 adipocyte differentiation. 3T3-L1
preadipocytes were differentiated into adipocytes in the absence or presence of Oligonol (10, 25, or 50𝜇g/mL) for 8 days. (a) Total RNA was
isolated from 3T3-L1 adipocytes at days 2, 4, and 8 during differentiation. mRNA expressions of PPAR𝛾, C/EBP𝛼, C/EBP𝛽, and C/EBP𝛿were
analyzed by quantitative RT-PCR. All gene expressions were normalized using GAPDH as a reference gene. (b) Protein expression levels of
PPAR𝛾 and C/EBP𝛼 were analyzed by Western blot analysis. Cell lysates were collected from 3T3-L1 cells at days 4 and 8 after induction
of adipocyte differentiation. Values are mean ± SEM of three independent experiments carried out in triplicates. ∗𝑃 < 0.05, ∗∗𝑃 < 0.01,
∗∗∗
𝑃 < 0.005 compared with untreated adipocytes at day 2. #𝑃 < 0.05, ##𝑃 < 0.01, ###𝑃 < 0.005 compared with untreated adipocytes at day
4. $𝑃 < 0.05, $$𝑃 < 0.01, $$$𝑃 < 0.005 compared with untreated adipocytes at day 8 at each gene expression.
and C/EBP𝛿 relative to untreated cells in a dose-dependent
manner, whereas mRNA levels of C/EBP𝛽 were not affected
by Oligonol (Figure 2(a)). Protein levels of PPAR𝛾 and
C/EBP𝛼 were also confirmed by Western blot analysis.
As expected, PPAR𝛾 and C/EBP𝛼 were highly induced
during adipocyte differentiation, and Oligonol significantly
inhibited protein levels of both transcription factors in a
dose-dependent manner. Inhibitory effect of Oligonol was
maintained until day 8, the termination stage of 3T3-L1
differentiation (Figure 2(b)).
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Figure 3: Effect of Oligonol on the expression of adipogenesis-related genes during 3T3-L1 adipocyte differentiation. 3T3-L1 preadipocytes
were differentiated into adipocytes in the absence or presence of Oligonol (10, 25, or 50𝜇g/mL) for 8 days. (a) Oligonol inhibited the mRNA
expressions of aP2, GLUT4, and Adiponectin during differentiation. The gene expressions were analyzed by quantitative RT-PCR. All gene
expressions were normalized using GAPDH as a reference gene. (b) Protein expression levels of aP2, GLUT4, and adiponectin were analyzed
byWestern blot analysis in 3T3-L1 adipocytes treatedwithOligonol. Cell lysates were collected from3T3-L1 cells at days 4 and 8 after induction
of adipocyte differentiation. Values are mean ± SEM of three independent experiments carried out in triplicates. ∗𝑃 < 0.05, ∗∗𝑃 < 0.01,
∗∗∗
𝑃 < 0.005 compared with untreated adipocytes at each gene expression.
3.3. Effect of Oligonol on the Expression of Adipogenesis
Markers. Since Oligonol exhibited antiadipogenic effects in
the early stage, we hypothesized that the target gene expres-
sion of those transcription factors might be downregulated.
Indeed, the mRNA levels of markers associated with the
final stage of adipogenesis, including adipocyte protein 2
(aP2), glucose transporter 4 (GLUT4), and adiponectin, were
significantly reduced by Oligonol (Figure 3(a)). Western blot
analysis confirmed the expression levels of adipogenesis-
associated genes at the protein level. Consistent with the
results in Figure 2, protein expressions of aP2, GLUT4, and
adiponectin were significantly reduced in 3T3-L1 cells by
continuous treatment of Oligonol (Figure 3(b)).
3.4. Effect of Oligonol on the Expression of Lipogenic Genes
and Lipid Accumulation. During adipocyte differentiation,
fibroblast-like preadipocytes convert to a spherical shape
and accumulate lipid droplets [2]. Because Oligonol signif-
icantly inhibited the accumulation of lipid droplet in 3T3-
L1 adipocytes, we evaluated whether Oligonol could inhibit
the synthesis of fats by measuring triglyceride contents. 3T3-
L1 preadipocytes were induced into differentiation in the
absence or presence of Oligonol, and triglyceride content
was quantified on day 8 of the differentiation periods.
As seen in Figure 4(a), 3T3-L1 adipocytes cultured in a
medium containing Oligonol displayed reduced intracellular
triglyceride content in a dose-dependent manner.The release
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Figure 4: Effect of Oligonol on lipid biosynthesis and lipolysis in 3T3-L1 adipocytes. 3T3-L1 preadipocytes were differentiated into adipocytes
with the absence or presence of Oligonol (10, 25, or 50𝜇g/mL) for 8 days. (a) Oligonol reduced TG content during differentiation of 3T3-
L1 adipocyte. 3T3-L1 preadipocytes were differentiated in the absence or presence of Oligonol for 8 days, and the lipid accumulation was
measured by triglyceride assay. (b) Oligonol inhibited the mRNA expressions of lipogenic gene, ACC, FAS, and SCD during differentiation.
The gene expressions were analyzed by quantitative RT-PCR. All gene expressions were normalized using GAPDH as reference gene. (c)
Protein expression levels of phospho-ACC, ACC, and FAS were analyzed byWestern blot analysis in 3T3-L1 adipocytes treated with Oligonol.
Cell lysates were collected from 3T3-L1 cells at days 4 and 8 after induction of adipocyte differentiation. (d) Glycerol release into the
medium was quantified in fully differentiated 3T3-L1 adipocytes treated with Oligonol (10, 25, or 50𝜇g/mL). Values are mean ± SEM of
three independent experiments carried out in triplicates. ∗𝑃 < 0.05, ∗∗𝑃 < 0.01, ∗∗∗𝑃 < 0.005 compared with untreated adipocytes.
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into adipocytes with the absence or presence of Oligonol (10, 25, or 50𝜇g/mL) for 8 days. (a) Oligonol decreased the serine phosphorylation of
Akt in 3T3-L1 adipocytes. (b) Oligonol phosphorylated AMPK in a dose-dependent manner, and inversely attenuated the phosphorylation of
mTOR-S6K in 3T3-L1 adipocytes as compared to untreated adipocytes. (c) Oligonol decreased the serine phosphorylation of FOXO1 in 3T3-
L1 adipocyte. Cell lysates were collected from 3T3-L1 cells at days 4 and 8 after induction of adipocyte differentiation. Western blot analysis
was performed using antibodies specific for the proteins indicated. The data shown are representative of three independent experiments.
of triglycerides into the conditioning media was also
reduced.
Reduction of triglyceride content was observed in the
cells treated with Oligonol, suggesting a role for Oligonol
in lipogenesis. Acetyl-CoA carboxylase (ACC) and fatty
acid synthase (FAS) are the primary enzymes involved in
lipogenesis, and the genes encoding them are the target genes
of PPAR𝛾 and C/EBP𝛼. At day 8, the mRNA levels of ACC
and FAS were found to increase in fully differentiated 3T3-L1
adipocytes, whereas their mRNA levels were decreased with
increasing dose ofOligonol in 3T3-L1 adipocytes. In addition,
Oligonol also reduced the mRNA expression of other genes
that are involved in lipid biosynthesis, such as stearoyl CoA-
desaturase (SCD1) and farnesyl diphosphate synthase (FDPS)
(Figure 4(b)). Western blot analysis also reconfirmed that
Oligonol reduced the protein levels of phospho-ACC (Ser79)
and FAS in 3T3-L1 adipocytes demonstrating that Oligonol
has an antilipogenic effect on 3T3-L1 cells (Figure 4(c)).
3.5. Effect of Oligonol on Lipolysis in 3T3-L1 Adipocytes. We
also extended our investigation of Oligonol on antiobe-
sity effects by quantifying lipolysis of 3T3-L1 adipocytes.
To examine whether Oligonol stimulated the lipolysis of
3T3-L1 adipocytes, cells were fully differentiated for 8 days
and treated with Oligonol for the next 48 hrs. Free glycerol
contents in a conditioning medium were measured as an
indicator of lipolysis. As shown in Figure 4(d), Oligonol
increased the significant amount of glycerol release. Glycerol
release was higher in Oligonol treated 3T3-L1 cells at as low
as 10 𝜇g/mL, and maximal glycerol release was observed at
25 𝜇g/mL of Oligonol concentration.
3.6.TheEffect ofOligonol on the Regulation of theAkt Signaling
Pathway during 3T3-L1 Differentiation. We then investigated
the state of the serine/threonine kinase Akt activation during
3T3-L1 adipogenesis and determined the effect of Oligonol
on the molecular pathway triggered by Akt. Cell lysates were
prepared from days 4 and 8 after initiation of differentia-
tion and immunoblotted with antibodies against phosphor-
Akt (Ser473) and total Akt. During normal differentiation
with 3T3-L1 cells, we observed an increased level of Akt
phosphorylation, which reflects Akt’s enzymatic activity. In
the presence of Oligonol, the expression of phospho-Akt
was reduced without affecting total Akt protein expression
in a dose-dependent manner (Figure 5(a)). In addition, the
pattern of phospho-Akt expression correlated with PPAR𝛾
and C/EBP𝛼 expression (Figure 2(b)).
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Activation of Akt regulates a diverse array of biologi-
cal processes [9], many of which could contribute to the
role of Akt in driving adipogenesis. Mammalian target of
rapamycin (mTOR) is a critical downstream signaling protein
that promotes both adipogenesis and lipogenesis [10] by
controlling PPAR𝛾 and sterol regulatory element-binding
protein-1 (SREBP-1). On the basis of the result that Oligonol
inhibited Akt activation, we hypothesized that mTOR signal-
ing pathway could be suppressed in 3T3-L1 adipocytes under
Oligonol treatment. Similar to the result of Akt inactivation,
the phosphorylation of mTOR was reduced in 3T3-L1 cells
in the presence of Oligonol. This change was paralleled by
the reduction of downstream signaling proteins, phospho-
ribosomal protein S6 kinase (S6K), ribosomal protein S6
(S6P), and transcription factor SREBP-1 expression, whereas
AMP-activated protein kinase (AMPK) was phosphorylated
by Oligonol treatment (Figure 5(b)).
We also investigated the phosphorylation of the tran-
scription factor forkhead box protein O1 (Foxo1) in 3T3-
L1 adipocytes treated with Oligonol. To investigate the
regulation of Foxo1 in adipocytes, we performed Western
blotting with a phospho-specific antibody against Thr24,
the site for sufficient nuclear exclusion of Foxo1 [11, 12].
Foxo1 phosphorylation was detectable and remained until
day 8 through the course of adipocyte differentiation. How-
ever, Oligonol significantly decreased the Foxo1 phospho-
rylation in agreement with Akt inactivation (Figure 5(c)).
These results demonstrate that Oligonol suppresses the Akt
activation, which leads to inhibition of its substrate Foxo1
phosphorylation.
4. Discussion
In this study, we investigated the effect of Oligonol on
adipocyte differentiation using mouse 3T3-L1 cells as a
model system. Oligonol inhibited the differentiation of 3T3-
L1 preadipocytes into adipocytes, and our data suggest that
this effect is through inhibition of the ATK-mTOR pathway,
triglyceride accumulation, and lipogenesis.
Adipocyte differentiation is mediated by sequential acti-
vation of a complex transcriptional cascade. In response
to an adipogenic induction, 3T3-L1 preadipocytes undergo
mitotic clonal expansion by dramatic induction of C/EBP𝛽
and C/EBP𝛿 at the first stage of adipogenesis. Then, C/EBP𝛽
and C/EBP𝛿 promote the expression PPAR𝛾 and C/EBP𝛼,
the central transcription factors in adipocyte differentiation.
PPAR𝛾 and C/EBP𝛼 cross-regulate each other through a
positive feedback loop and act synergistically to promote
terminal differentiation by transactivating target genes, such
as aP2, GLUT4, and adiponectin, which are commonly used
as adipocyte markers [2].
Oligonol is a lychee fruit-derived low-molecular form of
polyphenol containing catechin-type monomers and lower
oligomers of proanthocyanidin [13]. It is widely accepted that
many polyphenols produce antiobesity effects through differ-
ent targets. For instance, epigallocatechin-3-gallate (ECCG,
a flavonoid from tea extract) has been shown to reduce
mRNA expression of PPAR𝛾 and C/EBP𝛼 without affect-
ing C/EBP𝛽 or C/EBP𝛿 [14], whereas Citrus aurantium
flavonoids reduced the expression of C/EBP𝛽, C/EBP𝛼,
and 𝛼PPAR𝛾 [15]. Genistein (a soy-derived isoflavone) and
resveratrol (a stilbenoid from grapes) block adipogenesis by
targeting adipogenesis-associated transcription factors [16],
while lycopene (a carotenoid in tomato) does not modu-
late adipogenesis in 3T3-L1 but prevents obesity-induced
metabolic syndrome through regulation of adipokines and
inflammatory responses [6, 17]. Furthermore, Oligonol has a
better lipolytic effect than ECCG, and combined treatment of
both drugs increases lipolytic effect [18].These results support
the notion that mixture of several polyphenol compounds
helps to reduce obesity more effectively because each com-
pound targets different molecules and increases a synergistic
antiobesity effect.
To determine the stage of differentiation during which
Oligonol inhibits adipogenesis, we investigated the expres-
sion levels of the critical transcription factors PPAR𝛾,
C/EBP𝛼, and C/EBP𝛽 isoforms. Our results indicated that
mRNA expression of PPAR𝛾 and C/EBP𝛼 was downregu-
lated by Oligonol, whereas mRNA expression of C/EBP𝛽
was not affected (Figure 1). Microscopic inspection and
Oil Red O staining also revealed that Oligonol treatment
remarkably reduced lipid accumulation in 3T3-L1 cells and
maintained the cells in a preadipocyte phenotype. Addition-
ally, Oligonol significantly reduced GLUT4 and adiponectin
expression compared to that in fully differentiated adipocytes
(Figure 3(b)). These results indicated that Oligonol inhibited
the differentiation of 3T3-L1 cells at the early phase of
adipogenesis by repressing the expression of the master regu-
lators PPAR𝛾 and C/EBP𝛼 during adipocyte differentiation.
Decreased lipid content and reduction of lipogenic gene
expression were an obvious consequence of antiadipogenic
effect of Oligonol in fully differentiated adipocytes.
It is noteworthy that Oligonol increases lipolysis. Previ-
ously, Oligonol has been shown to decrease the epididymal
white adipose tissue mass of high fat diet-fed mice [6]
and to enhance lypolysis in primary adipocytes through
activation of the ERK1/2 pathway [7]. Consistent with those
reports, treatment of Oligonol increased the glycerol release
from fully differentiated 3T3-L1 adipocytes (Figure 4). Our
study mainly focused on the effect of Oligonol on inhibition
of adipogenesis; however, a concomitant lipolytic effect of
Oligonol suggests that Oligonol can be developed as a dual
antiobesity therapeutic agent.
Insulin is an essential ingredient for inducing adipo-
genesis. The Akt pathway is a downstream function of
insulin signaling that is critically involved in adipocyte
differentiation. RNAi or knockout for Akt gene in mouse
model displays severe defects in adipocyte differentiation
[19, 20], whereas overexpression of constitutively active Akt
enhanced adipocyte differentiation and glucose uptake in
3T3-L1 preadipocytes [21]. Moreover, Akt activation inhibits
downstream substrates such as GSK3𝛽 and Foxo1, which
directly regulate PPAR𝛾, C/EBP𝛽, and C/EBP𝛼 [22, 23].
The fact that Oligonol markedly inhibited Akt activation
(Figure 5) strongly suggest that this may be the underlying
molecular mechanism through which Oligonol inactivates
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PPAR𝛾 and C/EBP𝛼 during early phase in 3T3-L1 adipocyte
differentiation.
Adipocyte differentiation is also closely linked to the
mammalian target of rapamycin (mTOR) pathway. It has
been previously demonstrated that treatment with rapamycin
(also known as sirolimus) during 3T3-L1 adipocyte dif-
ferentiation resulted in the reduction of both mRNA and
protein levels of PPAR𝛾 and C/EBP𝛼, thereby indicating that
mTOR inactivation prevents adipocyte differentiation [24].
As PPAR𝛾 and C/EBP𝛼 appear to be specific target tran-
scription factors of Oligonol, we tested the effect of Oligonol
on the mTOR pathway in 3T3-L1 cells. Oligonol attenu-
ated phosphorylation of both mTOR and the downstream
substrate p70S6K (Figure 5), suggesting that the action of
Oligonol is similar to that of rapamycin in 3T3-L1. Prolonged
treatment of rapamycin inhibits adipocyte differentiation
in 3T3-L1 cells [25, 26] and in human primary adipocytes
[19]. One the other hand, AMPK, an upstream molecule of
mTOR, was phosphorylated by Oligonol treatment. Growing
evidences reported that AMPK is a new molecular target
of various phytochemicals such as curcumin, flavonoids,
and polyphenols in the prevention and treatment of cancers
[27]. Anthocyanin, a flavonoid, was demonstrated to activate
AMPK, leading to reduction in mTOR phosphorylation and
inhibiting cancer cell growth [28]; Fisetin induces apoptosis
by activating AMPK and suppressing mTOR in non-small
lung cancer [29] and prostate cancer cells [30]. In another
study, curcumin stimulates AMPK activation resulting in
downregulation of PPAR𝛾 in 3T3-L1 cells and in COX-2 in
MCF-7 breast cancer cells [31]. Moreover, synthetic AMPK
activator also supported the evidence that AMPK regulates
signal of PPAR𝛾 in 3T3-L1 adipocytes. Further studies will
be necessary, but it is very likely that Oligonol blocks the
activation of the Akt-mTOR signaling cascade, which then
subsequently suppresses the adipogenic transcription factors
PPAR𝛾 and C/EBP𝛼.
Although mTOR appears to be a good target for antiobe-
sity therapy, conflicting clinical cases have reported problems
associated with mTOR inhibition. For example, rapamycin
is a widely used immunosuppressant used to prevent graft
rejection in organ transplantation. One of the major side
effects associated with rapamycin is dyslipidemia character-
ized by elevating serum cholesterol and triglycerides levels
[32, 33]. Transplantation recipients receiving extended treat-
ment with rapamycin also exhibit diabetes-like symptoms,
including reduced glucose tolerance and insulin resistance
[34]. Such adverse effects are potentially caused by the
different functions of two different complexes of mTOR,
mTORC1, and mTOR2, in the liver [35]. However, very
little is known regarding the mechanism through which
deregulation of lipid metabolism occurs. mTOR-mediated
antiadipogenic effect of Oligonol in 3T3-L1 cells may suggest
a tissue-specific function of the mTOR pathway in lipid
homeostasis. On the other hand, lipolytic effect of Oligonol
[7, 18] suggests that it performs a second function as
an antiobesity reagent through inhibition of adipogenesis
and activation of lipolysis. Our observation that Oligonol
inhibits angiogenesis in adipocytes will provide a rationale
for evaluating Oligonol as a potential antiobesity reagent
in vivo.
5. Conclusion
The aims of this study were to investigate a potential antiadi-
pogenic effect of Oligonol and to explore the underlying
molecular mechanisms on adipocyte differentiation. We
showed that Oligonol significantly suppressed adipogenic
process by inhibiting the expression of C/EBP𝛼, C/EBP𝛿,
and PPAR𝛾 and reducing lipid accumulation in 3T3-L1
adipocytes. Oligonol inhibited protein phosphorylation of
Akt and the downstream signaling proteins mTOR and
p70S6K during adipocytes differentiation.Therefore, we pro-
pose that Oligonol inhibits the Akt-mTORpathway in 3T3-L1
cells, resulting in the prevention of adipogenesis at an early
stage of adipocyte differentiation. These results suggest that
Oligonol has a beneficial effect on prevention and treatment
of obesity.
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